• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Eosinophilic Annular Erythema due to Certolizumab Pegol Therapy for Rheumatoid Arthritis Post-COVID-19 Vaccine.

作者信息

Bassi Andrea, Piccolo Vincenzo, Ginori Alessandro, Galippi Grazia, Mazzatenta Carlo

机构信息

Division of Dermatology, Azienda USL Toscana Nord Ovest, Lucca, Italy.

Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy.

出版信息

Dermatol Pract Concept. 2023 Apr 1;13(2). doi: 10.5826/dpc.1302a95.

DOI:10.5826/dpc.1302a95
PMID:37196288
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10188144/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c157/10188144/256b3c2e7eef/dp1302a95g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c157/10188144/83369f59da72/dp1302a95g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c157/10188144/256b3c2e7eef/dp1302a95g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c157/10188144/83369f59da72/dp1302a95g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c157/10188144/256b3c2e7eef/dp1302a95g002.jpg

相似文献

1
Eosinophilic Annular Erythema due to Certolizumab Pegol Therapy for Rheumatoid Arthritis Post-COVID-19 Vaccine.聚乙二醇化赛妥珠单抗治疗新冠疫苗接种后类风湿关节炎所致嗜酸性环状红斑
Dermatol Pract Concept. 2023 Apr 1;13(2). doi: 10.5826/dpc.1302a95.
2
Certolizumab pegol: in rheumatoid arthritis.注射用培塞利珠单抗：治疗类风湿关节炎。
BioDrugs. 2009;23(6):407-17. doi: 10.2165/11202800-000000000-00000.
3
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.依奇珠单抗与阿达木单抗治疗类风湿关节炎的头对头比较：来自随机 EXXELERATE 研究的 2 年疗效和安全性结果。
Lancet. 2016 Dec 3;388(10061):2763-2774. doi: 10.1016/S0140-6736(16)31651-8. Epub 2016 Nov 15.
4
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.聚乙二醇化赛妥珠单抗（CDP870）用于成人类风湿关节炎的治疗。
Cochrane Database Syst Rev. 2011 Feb 16(2):CD007649. doi: 10.1002/14651858.CD007649.pub2.
5
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.聚乙二醇化赛妥珠单抗联合甲氨蝶呤在活动性类风湿关节炎的治疗中比安慰剂联合甲氨蝶呤显著更有效：一项为期52周的III期多中心随机双盲安慰剂对照平行组研究的结果。
Arthritis Rheum. 2008 Nov;58(11):3319-29. doi: 10.1002/art.23964.
6
Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.注射用培塞利珠单抗：用于治疗类风湿关节炎的综述。
Drugs. 2013 Jan;73(1):75-97. doi: 10.1007/s40265-013-0009-3.
7
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.类风湿关节炎患者既往使用改善病情抗风湿治疗失败后每4周一次赛妥珠单抗聚乙二醇单药治疗的疗效和安全性：FAST4WARD研究
Ann Rheum Dis. 2009 Jun;68(6):805-11. doi: 10.1136/ard.2008.099291. Epub 2008 Nov 17.
8
Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.聚乙二醇化赛妥珠单抗治疗类风湿关节炎的疗效与安全性：满足日常临床实践中风湿病学家的需求
BioDrugs. 2014 Apr;28 Suppl 1:S25-37. doi: 10.1007/s40259-013-0065-y.
9
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.聚乙二醇化赛妥珠单抗联合甲氨蝶呤治疗活动性类风湿关节炎的疗效和安全性：RAPID 2研究。一项随机对照试验。
Ann Rheum Dis. 2009 Jun;68(6):797-804. doi: 10.1136/ard.2008.101659. Epub 2008 Nov 17.
10
Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis.使用生物荧光成像比较赛妥珠单抗聚乙二醇化制剂、阿达木单抗和英夫利昔单抗在胶原诱导性关节炎小鼠炎症爪子中的分布。
J Immunol Methods. 2009 Aug 31;348(1-2):36-41. doi: 10.1016/j.jim.2009.06.009. Epub 2009 Jun 28.

引用本文的文献

1
TNF-alpha Inhibitors Induced Eosinophilia: A Case Report of an Undervalued Side Effect of Such Biologicals.肿瘤坏死因子-α抑制剂诱导的嗜酸性粒细胞增多症：此类生物制剂一种被低估的副作用的病例报告
Endocr Metab Immune Disord Drug Targets. 2025;25(6):503-507. doi: 10.2174/0118715303309437240703114340.

本文引用的文献

1
Refractory eosinophilic annular erythema treated successfully with dupilumab.使用度普利尤单抗成功治疗难治性嗜酸性粒细胞性环状红斑。
J Dtsch Dermatol Ges. 2020 Sep;18(9):1031-1032. doi: 10.1111/ddg.14254. Epub 2020 Sep 10.
2
Eosinophilic annular erythema in adults: report of two cases and review of the literature.成人嗜酸性粒细胞性环状红斑：两例报告并文献复习
An Bras Dermatol. 2017;92(5 Suppl 1):65-68. doi: 10.1590/abd1806-4841.20176373.
3
Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis.
聚乙二醇化赛妥珠单抗在免疫介导的炎症性疾病患者中的安全性概况：一项系统评价和荟萃分析。
Drug Saf. 2015 Oct;38(10):869-88. doi: 10.1007/s40264-015-0336-2.
4
Generalized granuloma annulare and non-Hodgkin's lymphoma.泛发性环状肉芽肿与非霍奇金淋巴瘤
Acta Derm Venereol. 2013 Jul 6;93(4):484-5. doi: 10.2340/00015555-1510.
5
Psoriatic skin lesions induced by certolizumab pegol.聚乙二醇化赛妥珠单抗诱导的银屑病皮肤病变
Arch Dermatol. 2010 Sep;146(9):1055-6. doi: 10.1001/archdermatol.2010.225.
6
A method for estimating the probability of adverse drug reactions.一种估算药物不良反应概率的方法。
Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154.